Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities (MEDULLA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04314752|
Recruitment Status : Recruiting
First Posted : March 19, 2020
Last Update Posted : May 17, 2022
The objectives of the proposed study are to develop and evaluate protocols for ethnic/racial minority-specific research using cancer registry data. In conjunction with the Cancer Registry of Greater California (CRGC), the investigators have developed procedures to identify, recruit, and survey ethnic/racial minority patients with MM. To pilot the study, the investigators aim initially to test the feasibility of this protocol by contacting 400 eligible patients (100 African Americans, 100 Latinos, 100 Asian American/Native Hawaiian/Pacific Islander-AANHPI and 100 non-Hispanic Whites as a comparison group) to conduct a pilot survey through which will ascertain etiological and survival-related factors for MM. Ultimately, the investigators hope the findings from this pilot will yield insight into the best practices for recruiting minorities with MM and serve as the basis for larger population-based studies of MM etiology and survival.
The next phase of this study is to expand the study to all 3 California Cancer Registries, including the Greater Bay Area Cancer Registry and the Los Angeles Cancer Surveillance Program and Cancer Registry of Greater California. We will increase the sample size to recruit atleast 1000 participants per racial/ethnic group. We will also request to increase the scope of the study to also continue a survivorship cohort.
|Condition or disease|
Eligible patients will include AAs, Latinos and AANHPIs who were diagnosed with a first primary, pathologically confirmed MM within the previous five years and who were at least 21 years of age at the time of diagnosis. We will also include, as a comparison group, non-Hispanic White patients. Patients must have been diagnosed in one of counties of California. Patients must be alive at the time of study and able to provide informed consent. We will not include those who are unable to consent, pregnant women, or prisoners.
Initially, in the pilot phase, we randomly selected 100 eligible patients from each race/ethnicity mentioned above to participate in the pilot study. As the pilot has been completed, we now aim to contact at recruit 1,000 patients per race/ethnic group reported to all three population cancer registries in the state, including the Greater Bay Area Cancer Registry and the Los Angeles Cancer Surveillance Program and Cancer Registry of Greater California until 2025. Patients diagnosis dates for the next phase of the study (June 2021-May 2025) will include diagnosis dates from 2018-2023, as there is a 2 year lag between patients cancer diagnosis and cancer registries information recorded.
Drs. Carvajal-Carmona and Cress have coordinated with MEDULLA investigators and CRGC research staff to develop a questionnaire for racial/ethnic minorities with Multiple Myeloma. The survey focuses on demographics, risk factors, cancer treatment, quality of life, and social determinants of health. All survey items are adapted from previously tested and validated surveys. The survey is expected to take approximately 30-45 minutes to complete.
CRGC staff, under Dr. Cress supervision, will identify eligible participants using the criteria described above based on diagnostic information in the CRGC database. The research team will be following California Cancer Registry policies and procedures for release of data. CRGC staff will extract patients contact information from the registry and will provide this information to research staff at UC Davis, who will work under Dr. Carvajal-Carmona's supervision.
The UC Davis Research team will initially mail each eligible participants a postcard and a survey study packet that will include: 1) Simple instruction sheet 2) An introductory letter that details the study 3) Information sheet that details on informed consent 4) Survey instruction sheet 5) A paper copy of the survey 5) Incentive selection sheet and option to continue to the second part of study 6) Brochures about the cancer registry and the UC Davis Comprehensive Cancer Center, and return pre-paid envelope.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||4000 participants|
|Target Follow-Up Duration:||5 Years|
|Official Title:||Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities|
|Actual Study Start Date :||September 1, 2020|
|Estimated Primary Completion Date :||May 30, 2025|
|Estimated Study Completion Date :||May 30, 2025|
- Review the response rate of mailed out surveys, compared by race/ethnicity and disease status [ Time Frame: 2025 ]Response Rate in percentage
- Response rate for saliva kits compared to survey response and determine if there is a disparity in participation between race/ethnic groups [ Time Frame: 2025 ]Response Rates in percentage
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04314752
|Contact: Luis Carvajal-Carmona, PhDemail@example.com|
|Contact: Angelica Perez, BSfirstname.lastname@example.org|
|United States, California|
|University of California Davis Comprehensive Cancer Center||Recruiting|
|Sacramento, California, United States, 95817|
|Contact: Luis Carvajal-Carmona, PhD 530-752-9654 email@example.com|
|Contact: Angelica Perez, BS 9167344563 firstname.lastname@example.org|
|Principal Investigator:||Luis Carvajal-Carmona, PhD||University of California, Davis|
|Principal Investigator:||Rosemary Cress, DrPh MPH||Cancer Registry of California|